抗血小板口服 Clopidogrel bisulfate is a platelet aggregation inhibitor. Clopidogrel is indicated for the reduction of atherosclerotic events in patients with atherosclerosis documented by recent stroke, recent myocardial infarction, or established peripheral arterial disease.

Clopidogrel bisulfate is a platelet aggregation inhibitor. It is metabolised by CYP450 enzymes to produce the active metabolite that inhibits platelet aggregation. The active metabolite of clopidogrel selectively inhibits the binding of adenosine diphosphate (ADP) to P2Y12 receptor and the subsequent platelet aggregation.

Patients with variant CYP2C19 genotype may have reduced conversion of clopidogrel to its active metabolite. Lower active metabolite exposure may result in reduced platelet inhibition and a higher rate of cardiovascular events. Discontinue clopidogrel 7 days prior to surgery or any event when a normal platelet effect is needed.

Hypersensitivity to clopidogrel

B

It is not known whether the drug is distributed into milk in humans. Discontinue nursing or the drug because of potential for severe adverse effects in infants.

Gastrointestinal hemorrhage (2.0%), intracranial hemorrhage (0.4% compared to 0.5% for aspirin), neutropenia (0.8%) or agranulocytosis, peptic, gastric or duodenal ulcers (1.2%), other GI symptoms including abdominal pain, dyspepsia, gastritis and constipation.

Adults: 75mg PO QD without regard to food. 300 mg tablet of clopidogrel is intended for use as a loading dose in patients suffering from acute coronary syndrome.